PEB - Pacific Edge Ltd

[Balance]

word is that one of the big holders is trying to unload a bunch of shares but no takers.

Price goes lower and lower until we see a big crossing?

[850man]

word is that one of the big holders is trying to unload a bunch of shares but no takers.

Price goes lower and lower until we see a big crossing?

I noticed a single 750K transaction go through the other day

[Habits]

I noticed a single 750K transaction go through the other day

ANZ are a big holder arent they, bought in around 80 possibly.

[Minerbarejet]

word is that one of the big holders is trying to unload a bunch of shares but no takers.

Price goes lower and lower until we see a big crossing?

Getting a strong sense of deja vu here.

[nztx]

Wonder if the A Bank are still happily onboard for the ride ?

[Maxtrade]

Getting a strong sense of deja vu here.

Implying what there Minor? That shea about to go off a cliff and SP delve back down to previous lows again? Same pattern as 2014 to 2020? Is that what you are referring to?

Definitely big risk holding fat this point in time right?

Still appears to be some faithful holders looking to acquire a few more around the 0.45 mark. How to know right now if she's a sinking ship on her way down again, or just passing through some choppy seas? Losses could be sizeable if SP were to break and drop down to previous levels. If that were to happen would happen fast and get caught in the sell down on a market open im sure if any further confirmation of negative news or substantial headwinds in US progression.

[Minerbarejet]

Implying what there Minor? That shea about to go off a cliff and SP delve back down to previous lows again? Same pattern as 2014 to 2020? Is that what you are referring to?

Definitely big risk holding fat this point in time right?

Still appears to be some faithful holders looking to acquire a few more around the 0.45 mark. How to know right now if she's a sinking ship on her way down again, or just passing through some choppy seas? Losses could be sizeable if SP were to break and drop down to previous levels. If that were to happen would happen fast and get caught in the sell down on a market open im sure if any further confirmation of negative news or substantial headwinds in US progression.

You only get losses by selling and now doesnt seem to me to be the time to do that.
Well at least not until the way ahead is clarified.
Murky waters rather than choppy seas.

The deja vue was a reaction to balances post which suddenly took on the appearance of a reincarnation of previous negative comment that he made over the years.

I assume you mean sheep rather than shea (butter) although it could be a slippery slope for a while.

[Minerbarejet]

Looks like business as usual with PEDUSA and progress in Asia as well.

View this email in your browser

Dear Customers and Friends of Cxbladder, Welcome to the August 2022 edition of the Cxbladder Bulletin. In this issue: BCAN's Think Tank: Engaging with Patients to Improve Standard of Care Highlighting Cxbladder's Clinical Utility at Urofair 2022 Case Study Discussion: Urofair 2022 Lunch Symposium - Advances in Bladder Cancer Diagnostics, Dr Pete Davidson STRATA Study Reaches 50% Enrolment Introducing David Sosa, VP Market Access & Reimbursement Upcoming Events

Think Tank: Engaging with Patients to Improve Standard of Care BCAN’s Think Tank, held in Denver Colorado earlier this month, is an annual conference that brings together bladder cancer patients, researchers and urologists from around the world. The relatively small size (a select group of several hundred attendees) coupled with the involvement of patients makes the event a unique forum to understand the patient perspective on standard of care and how it impacts quality of life. Think Tank was originally developed by Dianne Quale and her husband John to fill a gap not otherwise met in response to John’s positive diagnosis, i.e., a more collaborative and patient-centred approach to developing care solutions. As an event, Think Tank is designed to address that by, strongly encouraging interaction with patients, while prioritising research and researchers focused on improving standard of care. There were a range of interesting and productive sessions at this year’s event, but the one that most attracted attention relevant to our own activity as a sponsor and participant was that involving Dr Yair Lotan (UT Southwestern Medical Center at Dallas) and Dr Joshua Meeks (Northwestern Medicine, Chicago). During this session the pair focused on challenges associated with screening low risk patient populations presenting with non-visible blood in their urine. Their proposed model applies a biomarker test to any patient that has a urine analysis undertaken with an outcome of microhaematuria (3 – 25 red blood cells per high power field). Using this simple method, a biomarker test like Cxbladder would be applied to help inform the decision whether to undertake cystoscopy or not.

View the Session

Highlighting Cxbladder's Clinical Utility at Urofair 2022 After a two-year hiatus, Urofair 2022, the Singapore Urological Association’s annual scientific meeting held at Singapore’s Ng Teng Fong General Hospital, provided a welcome chance to speak directly to physicians. We used the opportunity to reconnect, highlighting the clinical utility of the Cxbladder suite in accurate rule-out and the prioritisation of those haematuria patients who require secondary work-up. Of particular interest was Dr Peter Davidson’s Lunchtime Symposium focused on the clinical pathway for haematuria evaluation established in New Zealand’s Canterbury Health Region. The primary care referral pathway lets GPs use Cxbladder Triage to help identify patients who do not require a referral to secondary care, thus avoiding an invasive cystoscopy procedure. The haematuria pathway developed in Canterbury has been implemented and operated successfully since early 2018, supported by a clinical review published in late 2020. It was this study, alongside other learnings from the pathway, that Dr Davidson spoke to in his presentation. Key outcomes linked to the Canterbury primary care haematuria pathway include: Patients are able access Cxbladder through their primary care provider i.e. closer to home, thereby avoiding a hospital visit. Fewer patients require referral to secondary care (39% of patients can be managed exclusively in primary care). Fewer patients require invasive procedures (>50% of patients do not require a cystoscopy). For patients referred to secondary care, the time to First Specialist Assessment is reduced by 25%. For patients where cancer is diagnosed, the pathway reduces the time to TURBT by 25%.

Cxbladder Case Study Discussion:

STRATA Study Reaches 50% Enrolment The Safe Testing of Risk for Asymptomatic Microhaematuria (STRATA) study is a double-blinded, randomised controlled trial – the gold standard of clinical utility evidence generation – that aims to further demonstrate how Cxbladder can safely risk stratify low-risk patients presenting with blood in their urine (haematuria) into those patients that may receive a less-intense evaluation for the presence of urothelial cancer and those that should continue with a standard evaluation. The quality of the clinical utility evidence generated in the STRATA study is expected to strengthen the case for incorporation of Cxbladder tests into the American Urological Association (AUA) guidelines. To this end, STRATA will specifically target the need for a reliable risk-stratification tool in the evaluation of haematuria patients so that investigation can be safely de-intensified, while the study will also confirm that there are no negative consequences to the patient when clinical decisions are informed by Cxbladder. A positive outcome from the STRATA trial will provide important clinical utility evidence showing that risk stratification can augment and improve the current AUA guidelines. As of mid-August, 386 patients have been enrolled across multiple sites in the US and Canada, and we’re now seeking a further 250 as STRATA moves towards full enrolment early in 2023.

Learn More

Introducing David Sosa, VP Market Access & Reimbursement It gives us great pleasure to announce the appointment of David Sosa as VP Market Access and Reimbursement, PEDUSA. David joined us in late June and will play a critical role in ensuring the optimal systems and processes are in place to facilitate insurance coverage, payment, test reimbursement, patient access and seamless engagement with all stakeholders in the healthcare value chain. To support our continued commercial success and improve operating efficiency, David will have responsibility for medical policy and contracting efforts, while he will also play a key role in piloting business strategies in the Americas. David brings to Pacific Edge more than 25 years’ experience working with pharmaceutical companies in the US, including most recently Decipher Biosciences, which provides urologic cancer tests, and MDxHealth, which provides tests for the early detection of clinically significant prostate cancer.

Learn More

Stop By and See Us at an Upcoming Event:

9 SEPT 2022 Canterbury Urology Society Trust Study DayThe Canterbury Urology Society Trust Study Day will he held on September 9 in Christchurch, NZ.

9 SEPT 2022 National Rural Health Conference (NRHC)This year's National Rural Health Conference (NRHC) will be held September 9-10 in Christchurch, NZ.

5 OCT 2022 Urology Association of Asia (UAA) CongressThis year's annual Urology Association of Asia meeting is planned October 5-8 in Sydney, Australia.

[Balance]

The deja vue was a reaction to balances post which suddenly took on the appearance of a reincarnation of previous negative comment that he made over the years.

I pass on pertinent information which I picked up from one of my broking contacts - not only to explain why the sp has been falling but to caution posters here to watch out for what (a big crossing) could turn around the sp.

Frankly, I believe you are in too donkey deep in PEB now to view posts objectively.

I have PEB shares still (residual from the big gains I made) and have every intention to stick with them towards the final conclusion - which could be oblivion if the LCD decision is not reversed. Happy to accept that scenario but it does not blind me to what is driving the sp week to week.

word is that one of the big holders is trying to unload a bunch of shares but no takers.

Price goes lower and lower until we see a big crossing?

[Minerbarejet]

Ill just sit and watch with my relatively miner collection - no hurry - and continue to post information that comes to hand

that others may have missed in the process or decided it wasnt worthy of comment here.

No Secret Squirrels here either.

The LCD "decision" is only a draft proposal that will be getting "plenty of input" from most interested parties.

Any big crossings may come from those funds committed to only holding NZX 50.

Both in and out.